Paradigm Biocapital Advisors LP increased its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 90.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,772,211 shares of the company's stock after acquiring an additional 840,731 shares during the quarter. MoonLake Immunotherapeutics comprises about 3.3% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 11th biggest holding. Paradigm Biocapital Advisors LP owned about 2.77% of MoonLake Immunotherapeutics worth $95,965,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. PNC Financial Services Group Inc. increased its stake in shares of MoonLake Immunotherapeutics by 3.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock worth $460,000 after acquiring an additional 320 shares in the last quarter. Deutsche Bank AG increased its stake in shares of MoonLake Immunotherapeutics by 59.8% in the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after acquiring an additional 338 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of MoonLake Immunotherapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock worth $3,192,000 after acquiring an additional 540 shares in the last quarter. DnB Asset Management AS increased its stake in shares of MoonLake Immunotherapeutics by 11.3% in the 4th quarter. DnB Asset Management AS now owns 8,356 shares of the company's stock worth $452,000 after acquiring an additional 847 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its stake in shares of MoonLake Immunotherapeutics by 18.4% in the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock worth $354,000 after acquiring an additional 1,013 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.
MoonLake Immunotherapeutics Stock Down 0.1%
Shares of NASDAQ MLTX traded down $0.04 during trading on Friday, reaching $37.62. 351,510 shares of the company traded hands, compared to its average volume of 356,542. The firm has a 50 day simple moving average of $38.40 and a 200-day simple moving average of $44.73. The stock has a market capitalization of $2.41 billion, a PE ratio of -29.16 and a beta of 1.31. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $58.26.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same quarter in the previous year, the company posted ($0.22) earnings per share. As a group, research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on MLTX. Wedbush reiterated an "outperform" rating and issued a $80.00 price target (up from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday. Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price objective for the company. The Goldman Sachs Group reduced their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $66.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $81.67.
Read Our Latest Stock Report on MLTX
About MoonLake Immunotherapeutics
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Recommended Stories
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
